阴道雌激素处方与复发尿路感染女性严重不良结局风险降低相关
基于Epic Cosmos数据库分析,纳入1,891,956例复发尿路感染女性,其中5.1%在第二次尿路感染后2个月内接受阴道雌激素处方,94.9%未接受。各年龄组(20-39、40-54、55-69、70-99岁)中,阴道雌激素处方与脓毒症、住院及全因死亡的较低比值比相关。
要点
- 复发尿路感染女性中仅5.1%在2个月内接受阴道雌激素处方。
- 各年龄组阴道雌激素处方者脓毒症、住院及死亡风险均低于未处方者。
- 脓毒症发生率处方组4.2%-10.4%,未处方组8.5%-24.1%。
核心结论
- 复发尿路感染诊断后2个月内接受阴道雌激素处方与各年龄组严重不良结局(脓毒症、住院、死亡)的较低比值比相关。
研究设计与样本
- 基于Epic Cosmos数据库的回顾性分析,纳入1,891,956例复发尿路感染女性(定义为1-6个月内两次独立编码的尿路感染)。
主要发现
- 97,109例(5.1%)在第二次尿路感染后2个月内接受阴道雌激素处方,1,794,847例(94.9%)未接受。
- 脓毒症发生率处方组4.2%-10.4%,未处方组8.5%-24.1%,OR 0.2-0.5(各年龄组)。
- 住院发生率处方组7.5%-12.0%,未处方组15.7%-27.5%,OR 0.3-0.6。
- 死亡率处方组0.3%-3.9%,未处方组0.8%-9.6%,OR 0.2-0.4。
关键数值与推荐
- 复发尿路感染定义为1-6个月内两次独立编码的尿路感染。
- 阴道雌激素处方分类为从未接受或在第二次尿路感染后2个月内接受。
- 结局评估在纳入后8年内进行,包括脓毒症、住院和全因死亡。
临床怎么用
- 对于复发尿路感染女性,可考虑在诊断后2个月内处方阴道雌激素以降低严重不良结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore rates of serious adverse outcomes (sepsis, hospital admission, and death) in women with rUTI who were prescribed vs not prescribed vaginal estrogen. METHODS: We used the Epic Cosmos database to identify women with rUTI, which we defined as 2 separate coded UTIs within 1-6 months. Vaginal estrogen prescription classification was either (1) never received or (2) received within 2 months of the second UTI. Outcomes were assessed within 8 years of inclusion (second UTI with or without a documented prescription) and included sepsis, hospital admission, and all-cause mortality. Age-stratified odds ratios (OR) with 95% confidence intervals (CI) were calculated. RESULTS: Of 1,891,956 females with rUTI, 97,109 (5.1%) received a prescription within 2 months and 1,794,847 (94.9%) did not. Across age groups (20-39, 40-54, 55-69, and 70-99 years), vaginal estrogen prescription was associated with lower odds of sepsis, hospitalization, and death. Sepsis occurred in 4.2%-10.4% of estrogen recipients vs 8.5%-24.1% of nonrecipients (OR 0.2-0.5 across age groups). Hospitalization occurred in 7.5%-12.0% of recipients compared with 15.7%-27.5% of nonrecipients (OR 0.3-0.6). Mortality increased with age in both groups but remained lower among estrogen recipients at 0.3%-3.9% vs 0.8%-9.6% in nonrecipients (OR 0.2-0.4 across age groups). CONCLUSION: Vaginal estrogen prescription within 2 months of rUTI diagnosis is associated with lower odds of serious adverse outcomes across age groups.
引用
- LaClair J, Visingardi J, Wells B, et al. Vaginal Estrogen Prescription is Associated with Reduced Risk of Serious Adverse Outcomes in Women of All Age Groups with Recurrent Urinary Tract Infection: An Epic Cosmos Database Analysis. Urology. 2026. PMID: 42269780. doi:10.1016/j.urology.2026.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。